top of page
nccn guidelines myeloma.jpg

CHEMOTHERAPY PROTOCOLS AGGRESSIVE MYELOMA

DCEP
VDCEP
VDT PACE
DCEP

DCEP


DCEP Dosing Low to high based on toxicity profile patient can handle depending on risk factors, formulated by patient's oncologist.


CYCLOPHOSPHAMIDE (250;300;400 mg/m2/day) +
ETOPOSIDE (25;30;40 mg/md/day) +
CISPLATIN (7.5;10;15 mg/m2/day) +
DEXAMETHASONE 40 mg (D 1-4) 28 DAY CYCLE

DCEP (300/30/7.5)

​



Reference: NCT00200681 : IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma

 

​

 

VDCEP

VDCEP

VELCADE / BORTEZOMIB 1.3MG/M2 (D 1,4,8,11) + DCEP

​

Reference: NCT00200681 : IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma

​

​

DT PACE / VDT PACE

VDT PACE

​

 

VTD-PACE (INDUCTION)

VELCADE 1MG/M2 SQ (D 1,4,8,&11) +
THALIDOMIDE 200MG (D 4-7) + DEX 40MG (D 4-7) +
(CISPLATIN 10MG/M2 + ADRIA 10MG/M2 + ETOPOSIDE 40MG/M2 +CYTOXAN 400MG/M2) (D 4-7)

​

​

VTD-PACE (CONSOLIDATION)

VELCADE 1 MG/M2 SQ (D 1,4,8,&11) +
THALIDOMIDE (D 1-4) + DEX 40MG (D 1-4) +
(CISPLATIN 7.5MG/M2 + ADRIA 7.5MG/M2 + ETOPOSIDE 30MG/M2 +CYTOXAN 300MG/M2) (D 1-4)

​

​

Reference: NCT00083551: UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
 

bottom of page